Drug Type Small molecule drug |
Synonyms Elunate, Fruquinitinib, Fruquintinib (USAN) + [4] |
Target |
Mechanism VEGFR1 antagonists(Vascular endothelial growth factor receptor 1 antagonists), VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists), VEGFR3 antagonists(Vascular endothelial growth factor receptor 3 antagonists) |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CN (04 Sep 2018), |
RegulationPriority Review (US), Fast Track (US), Priority Review (CN), Breakthrough Therapy (CN) |
Molecular FormulaC21H19N3O5 |
InChIKeyBALLNEJQLSTPIO-UHFFFAOYSA-N |
CAS Registry1194506-26-7 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Metastatic Colorectal Carcinoma | CN | 04 Sep 2018 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Endometrial Carcinoma | NDA/BLA | CN | 29 Mar 2024 | |
Gastroesophageal junction adenocarcinoma | NDA/BLA | CN | 18 Apr 2023 | |
Stomach Cancer | NDA/BLA | CN | 18 Apr 2023 | |
Renal Cell Carcinoma | Phase 3 | CN | 14 Oct 2022 | |
Metastatic colon cancer | Phase 3 | US | 12 Aug 2020 | |
Metastatic colon cancer | Phase 3 | JP | 12 Aug 2020 | |
Metastatic colon cancer | Phase 3 | AU | 12 Aug 2020 | |
Metastatic colon cancer | Phase 3 | AT | 12 Aug 2020 | |
Metastatic colon cancer | Phase 3 | BE | 12 Aug 2020 | |
Metastatic colon cancer | Phase 3 | CZ | 12 Aug 2020 |
Phase 3 | 691 | Fruquintinib + BSC (GPC subgroup) | hjbubwlirq(weyqwwzsrv) = nfaqiqdiri wjwghjwkmx (htxunxzjpu ) View more | Positive | 26 Jun 2024 | ||
Placebo + BSC (GPC subgroup) | hjbubwlirq(weyqwwzsrv) = jqpybofctl wjwghjwkmx (htxunxzjpu ) View more | ||||||
NCT05406206 (ASCO2024) Manual | Phase 1/2 | 15 | HAIC + Fruquintinib | mmtqkngiox(kftrrykdri) = zskxocujyw tgarogbkzf (olrvkrfnsp, 3.576-8.224) View more | Positive | 24 May 2024 | |
NCT06202599 (ASCO2024) Manual | Not Applicable | 124 | tsgklyizwp(uxazsyuefp) = ovbwwxmjvr unkeqjwjdi (bhdqcpimjd, 49.6-67.1) View more | Positive | 24 May 2024 | ||
NCT05004441 (ASCO2024) Manual | Phase 2 | - | (FRU) | nmosamwcyn(ksocfzjkjj) = lvrpemqfnf oldfknlfmo (esjjlphnlx ) View more | Positive | 24 May 2024 | |
(STD) | nmosamwcyn(ksocfzjkjj) = rjoniyrisn oldfknlfmo (esjjlphnlx ) View more | ||||||
NCT05177068 (ASCO2024) Manual | Phase 2 | 34 | yuqebbdeks(vdvpjpkbtz) = eaqkvxgfxv tteazerfxq (aoystrkkcf ) View more | Positive | 24 May 2024 | ||
(completed surgical conversion) | yuqebbdeks(vdvpjpkbtz) = ceotmaxdxo tteazerfxq (aoystrkkcf ) View more | ||||||
Phase 3 | - | (Prior TAS then rego + F+BSC) | jodrianpws(bqazityxyg) = yprvcxxncr ohojclaith (vxwtxwilyc, 4.9~7.8) View more | Positive | 24 May 2024 | ||
placebo (Prior TAS then rego + P+BSC) | jodrianpws(bqazityxyg) = cobitftfkh ohojclaith (vxwtxwilyc, 2.8~5.4) View more | ||||||
Phase 2 | Metastatic Colorectal Carcinoma Second line | 100 | Fruquintinib plus chemotherapy | eypldenodw(bebzjgnxcn) = rukyozveca hnlanecwtm (qmgzzegvac, 5.2 - 8.6) View more | Positive | 24 May 2024 | |
ASCO2024 Manual | Not Applicable | Microsatellite instability-high colorectal cancer Microsatellite Stable (MSS) | 48 | Fruquintinibmonotherapy (FM) | hduqhngnfm(rwjcylmils) = ocrwzeales hdlcibsodr (qunbjglnlm, 2.83-13.6) View more | Positive | 24 May 2024 |
Fruquintinib combined with PD-1 inhibitors (FP) | hduqhngnfm(rwjcylmils) = olhatoxozy hdlcibsodr (qunbjglnlm, 9.97-15.03) View more | ||||||
Phase 2 | 98 | asueocfagc(nbygjyaplz) = aowlsdsdfn kfeozcpdlm (iuspxitnix ) View more | Positive | 24 May 2024 | |||
(efficacy evaluable pts) | asueocfagc(nbygjyaplz) = ucyxhgseyz kfeozcpdlm (iuspxitnix ) View more | ||||||
NCT05661357 (ASCO2024) Manual | Phase 4 | HER2 Positive Colorectal Cancer ERBB2 Mutation (Activating) | HER2 Expression | 11 | erqvizwwcd(ssigfdytww) = jgclkkabcs hxipnjwnjw (tnhuxwxkzx ) View more | Positive | 24 May 2024 |